KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $164.9 million.

  • Bio-Rad Laboratories' Cash from Operations rose 3276.97% to $164.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $532.2 million, marking a year-over-year increase of 1691.56%. This contributed to the annual value of $532.2 million for FY2025, which is 1691.56% up from last year.
  • As of Q4 2025, Bio-Rad Laboratories' Cash from Operations stood at $164.9 million, which was up 3276.97% from $120.9 million recorded in Q3 2025.
  • In the past 5 years, Bio-Rad Laboratories' Cash from Operations registered a high of $230.4 million during Q3 2021, and its lowest value of $11.0 million during Q3 2022.
  • For the 5-year period, Bio-Rad Laboratories' Cash from Operations averaged around $111.3 million, with its median value being $105.9 million (2021).
  • In the last 5 years, Bio-Rad Laboratories' Cash from Operations plummeted by 9522.5% in 2022 and then soared by 78818.18% in 2023.
  • Bio-Rad Laboratories' Cash from Operations (Quarter) stood at $170.9 million in 2021, then plummeted by 53.42% to $79.6 million in 2022, then increased by 1.76% to $81.0 million in 2023, then skyrocketed by 53.33% to $124.2 million in 2024, then surged by 32.77% to $164.9 million in 2025.
  • Its Cash from Operations was $164.9 million in Q4 2025, compared to $120.9 million in Q3 2025 and $116.5 million in Q2 2025.